Time For Big Pharma To Take Back Orphan Drugs
Executive Summary
The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.
You may also be interested in...
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Republican Senators request US Government Accountability Office quantify law’s impact and assess whether regulatory or legislative changes are needed. FDA plans ‘unbiased’ look at outcomes from law’s incentives, while NORD is developing data on total percentage of drug spending represented by orphan indications.
Trump Slams FDA Regulations In Joint Session Of Congress
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.